Heritage Pharmaceuticals Inc. has announced the immediate availability of Propranolol HCl Oral Tablets in 10, 20, 40, 60 and 80 mg strength. Heritage’s development and manufacturing partner, Ipca Laboratories Ltd., received final approval of its Abbreviated New Drug Application (ANDA) for an AB Rated equivalent of Inderal(R) on June 2, 2008. Propranolol Tablets are the generic equivalent of Inderal(R) Tablets formerly marketed by Wyeth. Propranolol has multiple cardiovascular related indications, including the management of hypertension, treatment of angina and atrial fibrillation. Propranolol had U.S. brand and generic sales of approximately $25 million for the 12-month period ending Dec. 31, 2007 according to IMS Health. Commenting on the launch, Heritage President & CEO, Jeffrey Glazer, stated, “the launch of Propranolol represents the first vertically integrated product from our strategic alliance with Ipca and will enable us to leverage the economies of scale of products made abroad while continuing to provide customers with high quality, cost efficient generic pharmaceutical products. We are pleased with the strength of Ipca’s development and manufacturing expertise and look forward to growing our product portfolio over 2008-09.”
